Other options for second-line therapy may require a specific molecular marker, such as capivasertib or alpelisib in combination with fulvestrant in PI3KCA/PTEN/mTOR altered tumours and trastuzumab deruxtecan inHER2-low cancers. This evidence concerns the gene MTOR and neoplasm.